Digestive Disease Week 2015
Digestive Disease Week is "the world's leading educational forum for academicians, clinicians, researchers, students and trainees working in gastroenterology, hepatology, GI endoscopy, gastrointestinal surgery and related fields." More than 14,000 gastroenterology professionals will attend DDW 2015, which will feature "interactive programming and the best basic, clinical and translational research."
Q&A With Karen Madsen From University of Alberta: Using Fecal Transplant to Fight Antibiotic Resistance
Q&A With Dina Kao From University of Alberta: Working to 'Advance the Science' of Fecal Microbiota Transplant
Q&A With Prashant Singh From Massachusetts General: Menopausal Hormone Therapy and its Role in Gastrointestinal Bleeding
Q&A With Luc Biedermann From University Hospital Zurich: Diagnosis Delay Has Serious Consequences for Patients with Celiac Disease
Q&A With Jessica Cohan From UCSF Medical School: How Much Information Do Patients Need for Ulcerative Colitis Surgical Procedures
Q&A With Zobair Younossi From Inova Fairfax Hospital: Hepatitis C Treatment Provides Fiscal Benefits as Well as Health Improvements
Q&A With Luca Cicalese From University of Texas Medical Branch Galveston: Scaffold Development Could Help Patients with Intestinal Issues
Q&A With Ayako Suzuki From the Central Arkansas Veterans Healthcare System: Using Data to Learn More About Drug Induced Liver Injury
According to research done on computer assisted propofol sedation patients see a faster recovery time by approximately 6 minutes on average. This can help not only the patients to leave the recovery area faster, but can also put less of a burden on the staff and location of their endoscopic procedure.
Patients recommended for screening colonoscopy often resist because the bowel cleansing regimen is unpleasant. In an abstract presented at the 2015 Digestive Disease Week conference in Washington, DC, Campbell Levy, MD, of Dartmouth-Hitchcock Medical Center in Lebanon, NH, and colleagues at other institutions reported on a novel edible product that achieves the desired results.
Fecal microbiota transplantation (FMT) is a proven therapy for recurrent C. difficile infection. A team of researchers from OpenBiome outlined plans for a depository for frozen stool from screened donors. The goal is to have a consistent and safe product for use by clinicians who treat patients with this ailment.